1. Voluntarily participating in the clinical study, fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF), willingness and capability to complete all the study procedures <br/ >2. Age 18-70 years (inclusive) at the time of signing ICF <br/ >3. Patients with laboratory confirmation of infection with SARS-CoV-2 by positive Rapid Antigen Test for SARS-CoV-2 at screening. <br/ >4. Recent onset (within 72 hours of time of consent) symptoms of mild COVID 19 with oxygen saturation (SpO2 > 94 %) and respiratory rate < 24 breaths/min. <br/ >5. For female subjects: evidence of post-menopause, or, for pre-menopause subjects, negative pretreatment urine pregnancy test <br/ >6. Eligible subjects of child-bearing age (female or male with female partner of childbearing age) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the study period and for at least 7 days following the last study treatment. <br/ >7. Not participating in any other interventional drug clinical studies before completion of the present study. <br/ >

1. Voluntarily participating in the clinical study, fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF), willingness and capability to complete all the study procedures <br/ >2. Age 18-70 years (inclusive) at the time of signing ICF <br/ >3. Patients with laboratory confirmation of infection with SARS-CoV-2 by positive Rapid Antigen Test for SARS-CoV-2 at screening. <br/ >4. Recent onset (within 72 hours of time of consent) symptoms of mild COVID 19 with oxygen saturation (SpO2 > 94 %) and respiratory rate < 24 breaths/min. <br/ >5. For female subjects: evidence of post-menopause, or, for pre-menopause subjects, negative pretreatment urine pregnancy test <br/ >6. Eligible subjects of child-bearing age (female or male with female partner of childbearing age) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the study period and for at least 7 days following the last study treatment. <br/ >7. Not participating in any other interventional drug clinical studies before completion of the present study. <br/ >

1. Voluntarily participating in the clinical study, fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF), willingness and capability to complete all the study procedures <br/ >2. Age 18-65 years (inclusive) at the time of signing ICF <br/ >3. Patients with laboratory confirmation of infection with SARS-CoV-2 by positive Rapid Antigen Test for SARS-CoV-2 at screening. <br/ >4. Recent onset (within 48 hours of time of consent) symptoms of mild COVID 19 with oxygen saturation (SpO2 > 94 %) and respiratory rate < 24 breaths/min. <br/ >5. For female subjects: evidence of post-menopause, or, for pre-menopause subjects, negative pretreatment urine pregnancy test <br/ >6. Eligible subjects of child-bearing age (female or male with female partner of childbearing age) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the study period and for at least 7 days following the last study treatment. <br/ >7. Not participating in any other interventional drug clinical studies before completion of the present study. <br/ >

1. Voluntarily participating in the clinical study, fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF), willingness and capability to complete all the study procedures <br/ >2. Age 18-65 years (inclusive) at the time of signing ICF <br/ >3. Patients with laboratory confirmation of infection with SARS-CoV-2 by positive Rapid Antigen Test for SARS-CoV-2 at screening. <br/ >4. Recent onset (within 48 hours of time of consent) symptoms of mild COVID 19 with oxygen saturation (SpO2 > 94 %) and respiratory rate < 24 breaths/min. <br/ >5. For female subjects: evidence of post-menopause, or, for pre-menopause subjects, negative pretreatment urine pregnancy test <br/ >6. Eligible subjects of child-bearing age (female or male with female partner of childbearing age) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the study period and for at least 7 days following the last study treatment. <br/ >7. Not participating in any other interventional drug clinical studies before completion of the present study. <br/ >